Prolymfocytární leukemie
| Title in English | Prolymphocytic leukemia |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | This capture summarizes a current knowledge of diagnostic algorithm and treatment of prolymphocytic leukemia (PLL) that is an agressive rare disease of a B or T cell origin. Due to the absence of disease specific cytologic and phenotypic markers a diagnostic process might be difficult. Prolymphocytic leukemia is frequently associated with functional defects of TP53 gene and for this subgroup of patients alemtuzumab is the treatment of choice. In contrast to B-PLL patients with a functional TP53 gene where a combination of rituximab, fludarabine, cyclophosphamide is a standard of therapy. Allogeneic stem cell transplantation still represents the only curative approach. |